Loading patent…
AssigneesKorea Advanced Institute of Science and Technology, Thor Therapeutics Inc., The Industry & Academic Cooperation in Chungnam National University (IAC)
InventorsJinkuk KIM, Minsung PARK, Minho SHONG, Joon Young CHANG, Sang-Hyeon JU, Hyunjung HONG, Hyon-Seung YI, Min Hee LEE
Estimating the term…
The present invention relates to: GFRAL-specific antisense oligomers targeting the GDNF family receptor alpha like (GFRAL) gene; and a pharmaceutical composition for preventing or treating obesity, diabetes, appetite loss, or cachexia, the pharmaceutical composition including the antisense oligomers. The antisense oligomers according to the present invention were found to effectively inhibit GFRAL expression in the body and exhibit amelioration effects in cancer cachexia animal models. Thus, the application of the antisense oligomers as an agent for treating obesity or cachexia through GFRAL expression inhibition is highly promising.
An oligomer capable of hybridizing with at least 13 consecutive nucleobases in an whole pre-mRNA of human GFRAL (GDNF family receptor alpha like) gene represented by SEQ ID NO:
Dependencies are inferred from the claim text.